Сhonluten
Biologically active food supplement СHONLUTEN® is a peptide complex containing amino acids: glu-
tamic acid, aspartic acid, glycine, which has a normalizing effect on the cells of the bronchial mucosa.
СHONLUTEN® is available in tablets or capsules with an active substance content of 0.100 mg.
The results of experimental studies have shown that СHONLUTEN® has a tissue-specific effect on
the cells of the bronchial mucosa, improves their trophism and has a regulatory effect on metabolic
processes in them, contributes to the normalization of functional and morphological changes in the
bronchial mucosa, reducing the risk of various inflammatory diseases of the bronchi and lungs. This
suggests the effectiveness of СHONLUTEN®’s use to restore the function of the respiratory system
in various inflammatory diseases.
Chronic bronchitis is a severe medical and social problem due to its high prevalence, growing sickness
rate, mortality, and enormous economic damage to society. Chronic bronchitis is the main form in the
structure of chronic nonspecific lung diseases (3, 4).
Medical treatment of chronic bronchitis includes the use of the following drugs (1, 2):
- Antibiotics (penicillin, kanamycin, oleandomycin);
- Sulfonomides (biseptol, madribone);
- Bronchodilators (aminophylline, ephedrine, salbutamol, phentolamine);
- Expectorants (bromhexine, thermopsis);
- Immunomodulators (thymalin, taktivin);
- Glucocorticoids (hydrocortisone, prednisolone, dexamethasone), etc.
Clinical trials of СHONLUTEN®were carried out at the Medical Center of the St. Petersburg Institute
of Bioregulation and Gerontology, SZO RAMS in patients with chronic bronchitis with an asthmatic
component in the period from November 2005 to February 2006.
CLINICAL CHARACTERISTICS OF PATIENTS
Treatment with СHONLUTEN® was carried out in 23 patients (15 men, 8 women) with a diagnosis
of chronic bronchitis with an asthmatic component, remission phase. The patients’ age ranged from
38 to 65 years.
Patients complained of coughing up phlegm, mainly in the morning, general weakness, sweating,
shortness of breath during physical activity, recurrent attacks of suffocation, sleep disturbances, and
headaches.
The duration of the course of the disease in patients was 3-10 years, and there were progressive dy-
namics of the development of the pathological process.
All patients previously received symptomatic and pathogenetic therapy for this disease.
The control group consisted of 19 patients with a similar disease who were prescribed traditional
treatment.
RESEARCH METHODS
СHONLUTEN®’s efficiency assessment was carried out by analyzing the patients’ complaints pro-
gression, general clinical examinations of blood and urine, and biochemical blood study using the
REFLOTRON apparatus (Boehringer Mannheim, Germany). Additionally, radiography of the lungs, mi-
croscopic examination of sputum, and analysis of the function of external respiration were performed.
RESEARCH RESULTS
It was found that the use of CHONLUTEN® against the background of conventional therapy in patients
with chronic bronchitis in 73% of cases contributed to an improvement in well-being, a decrease in
the frequency of coughing attacks, asthma attacks, and a decrease in the amount of sputum secreted.
The auscultation of the lungs in dynamics testified to the disappearance of dry, whistling, and buzzing
wheezing in some cases.
In the process of using CHONLUTEN®, a decrease in the microscopic structures of sputum was ob-
served: leukocytes, epithelial cells, Kurshman coils, which indicates a decrease in the inflammatory
and bronchospastic manifestations of the disease.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.